The user has been using finasteride, minoxidil, and a derma stamp for 3 months with significant improvement. They are now adding ketoconazole to their routine.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
The user has been managing hair loss with microneedling, Nutrafol, topical finasteride/minoxidil foam, LLLT, and Nizoral, and plans to add oral minoxidil. They are seeing improvement and are cautious about using oral finasteride due to past gynecomastia concerns.
The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.
The user is using topical finasteride 0.1%, minoxidil 5% twice daily, red light therapy, a multi-peptide serum, and a weekly oil hair mask with various oils and ingredients. They also use ketoconazole shampoo, condition their hair, and microneedle with a dermapen, seeking advice on any changes to their routine.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
The conversation discusses a 20-year-old transgender female's one-year experience with hair loss treatments, including Estradiol HRT, oral Finasteride, Bicalutamide, and Cyproterone. Specific treatments used for hair loss are oral Finasteride and potentially Estradiol as part of hormone replacement therapy.
A user reports significant hair density increase and new growth at the temples after two months of using finasteride, minoxidil, ketoconazole, dermarolling, MK-677, zinc, and vitamin D3, with shedding stopping a week ago. They recently added MK-677 to their regimen.
A 26-year-old is undergoing dutasteride mesotherapy with cuticapil serum and minoxidil tablets for hair loss, expecting results in a few months. The treatment is monthly, costs 4750 INR per session, and has shown no noticeable side effects so far.
A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.
A user shared 3 months of progress using daily Dutasteride 0.5mg and Minoxidil 5mg, with Dutasteride mesotherapy every 4 months. They prefer not to use additional treatments for now.
The conversation is about whether castor oil can be effectively used alone after microneedling without a penetration enhancer like DMSO or ethanol. The user believes microneedling-induced wounds might be enough for absorption.
The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.
User "Number_Worried00" is using a treatment stack for hair loss, including Minoxidil, Finasteride, Dutasteride, Estradiol, Cetirizine, and Pyrilutamide. Another user suggests that if the cause is vitamin deficiency or inflammation, the stack may not be effective.
A user is attempting to recover from severe hair loss using 1.25mg finasteride, 5mg topical minoxidil twice daily, pyrilutamide for a month, RU58841 for two weeks, and weekly microneedling at 1.5mm. They have seen new hair growth after two months and plan to continue the treatment for a year with the hope of regrowing enough hair for a transplant.
User considers scalp micropigmentation (SMP) for hair loss. Mixed opinions shared; some regret it, others satisfied. Choosing reputable clinic and technician is important.
The conversation discusses concerns about using hair fibers while microneedling, specifically the potential for clogging pores. It is suggested that microneedling should not cause bleeding.
The user transitioned from finasteride to Cyproterone and started using Minoxidil, resulting in healthier hair and regrowth. They plan to wean off Minoxidil in a year, depending on regrowth.
The user is looking for a PG-free solvent in the UK or EU to make their own pyrilutamide solution for hair loss and is currently using finasteride, considering minoxidil. They hope pyrilutamide will help stabilize their hair loss.
N-Acetyl-Cysteine (NAC) is being explored for treating hair loss, but users report mixed results. Some also mention using Quercetin and Resveratrol without significant hair improvement.
27F with androgenic alopecia since 17 seeks treatment. Tried spironolactone, caused low blood pressure; believes finasteride is safer and wants to try it.
A 34-year-old woman has been using a topical solution of 5% Minoxidil and 0.1% Finasteride since January 2026 to address hair thinning caused by PCOS and poor nutrition. She reports ongoing hair shedding but has improved her diet with whole foods and supplements.
Dutasteride mesotherapy is discussed as a potential treatment for hair loss, with some users suggesting it offers a slight boost when combined with oral minoxidil, though it's costly. Concerns about side effects and systemic absorption are noted, with alternatives like topical dutasteride and microneedling suggested for home use.
Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
The conversation discusses concerns about oral minoxidil potentially aging the face by affecting collagen, questioning its systemic effects. The user has successfully used topical minoxidil for years and is hesitant to switch to oral minoxidil.